Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · IEX Real-Time Price · USD
9.80
-0.14 (-1.41%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Neumora Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
124
Market Cap
1.56B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNMRA News
- 12 days ago - Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation - GlobeNewsWire
- 7 weeks ago - Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression - GlobeNewsWire
- 2 months ago - Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Neumora's early-stage schizophrenia drug study put on hold - Reuters
- 2 months ago - Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study - GlobeNewsWire
- 3 months ago - Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days - GlobeNewsWire
- 4 months ago - Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer - GlobeNewsWire